Orthopedia Stock Price, News & Analysis

OrthoPediatrics (NASDAQ: KIDS) reported strong financial results for Q4 and full year 2024. The company achieved record annual revenue of $204.7 million, up 38% from 2023, with domestic revenue increasing 45% and international revenue growing 15%.

Q4 2024 highlights include total revenue of $52.7 million, a 40% increase year-over-year, and adjusted EBITDA of $3.0 million, more than double compared to Q4 2023. The company helped over 34,000 children in Q4 and approximately 138,000 for the full year.

Key segment performance for 2024:

• Trauma and Deformity revenue: $145.1 million (+36%)
• Scoliosis revenue: $55.2 million (+45%)
• Sports Medicine/Other: $4.4 million (+11%)

For 2025, OrthoPediatrics projects revenue between $235.0-242.0 million, representing 15-18% growth, and expects adjusted EBITDA of $15.0-17.0 million.

OrthoPediatrics (Nasdaq: KIDS), a company specializing in pediatric orthopedics, has announced it will release its fourth quarter and full year 2024 financial results on Tuesday, March 4, 2025, after market close. The company will host a conference call at 4:30 p.m. ET on the same day to discuss the results.

Investors can access the conference call through a live and archived webcast available on the company's website at www.orthopediatrics.com in the Events & Presentations section of the Investors page. The webcast will remain available for replay for at least 90 days following the event.

OrthoPediatrics Corp. (NASDAQ: KIDS) has announced a distribution agreement with Thrive Orthopedics through its OrthoPediatrics Specialty Bracing (OPSB) division. The agreement covers three pediatric orthotic solutions:

1. The F3 Hero Pediatric AFO: A carbon fiber ankle foot orthosis for children with walking challenges due to cerebral palsy, spina bifida, or chemotherapy-related foot drop.

2. The TruStretch Pediatric Equinus Brace®: An above-the-knee brace for stretching gastroc-soleus muscles in children with equinus deformity.

3. The Thrive® Pediatric X-Glide Carbon Fiber Insoles: Available in rigid and flexible styles as lightweight gait training tools.

OrthoPediatrics (NASDAQ: KIDS) announced record preliminary unaudited revenue for 2024, reaching $204.7 million, a 38% increase from 2023's $148.7 million. The company's domestic revenue grew 45% to $161.1 million, while international revenue increased 16% to $43.6 million.

Fourth quarter 2024 revenue reached $52.7 million, up 40% year-over-year, with domestic revenue growing 52% to $42.9 million and international revenue rising 5% to $9.8 million. The company helped over 34,000 children in Q4 2024, surpassing 1.1 million children helped since inception.

For 2025, OrthoPediatrics projects revenue between $235-242 million (15-18% growth), with expected annual set deployment of $15 million and adjusted EBITDA of $15-17 million. The company highlighted strong performance in Trauma and Deformity, Scoliosis, and specialty bracing businesses.

OrthoPediatrics Corp. (KIDS) announced the expansion of its Specialty Bracing (OPSB) division into three new markets in Indiana, Colorado, and Florida. The OPSB division, launched in early 2024, aims to increase pediatric care access through new clinics and strategic acquisitions.

The company opened a new clinic in Indianapolis near Riley Children's Hospital and Peyton Manning Children's Hospital, established a new site within Nationwide Children's Hospital in Columbus, OH, acquired a clinic group in Colorado with plans for Denver area expansion, and acquired a clinic in Davie, Florida, serving as a foundation for statewide growth.

This expansion is part of OPSB's multi-year strategy to enhance access to non-operative pediatric orthopedic solutions through both greenfield clinics and strategic acquisitions, focusing on partnerships with pediatric orthopedic surgeons across different regions.

OrthoPediatrics Corp. (Nasdaq: KIDS) has expanded its Specialty Bracing portfolio with two new products: the OPSB Sensor System and MOVE-D™. The OPSB Sensor System is the company's first sensor solution, featuring Bluetooth connectivity that uploads wear-time data to an interactive app with gamification elements and cloud-based storage for healthcare provider monitoring. The MOVE-D™, acquired through license and distribution agreements with Innovation Lab, is a mechanical elbow brace designed to stabilize tremors in the dominant upper extremity for pediatric patients with movement disorders, improving daily activities performance.

The company's subsidiary, Boston Orthotics & Prosthetics, has been using thermal sensors in scoliosis braces for over 10 years, based on research showing correlation between brace wear time and treatment success.

OrthoPediatrics (Nasdaq: KIDS) announced its participation and Emerald-Level sponsorship at the 20th Annual International Pediatric Orthopaedic Symposium (IPOS) in Orlando, Florida, from December 3-7. The event, expecting over 500 pediatric orthopedic surgeons, will feature the company's exhibition booths showcasing their full product suite, including the new Enabling Technology division with 7D, 3-D Side, and Specialty Bracing division (OPSB).

The company will host several educational sessions, including discussions on rigid tibial nailing, bioresorbable implants, career launching, and spica cast usage. A pre-course innovation session focusing on creative solutions is also scheduled.

OrthoPediatrics (Nasdaq: KIDS) announces significant updates to its DF2® Brace, expanding its applications and market reach. The brace, previously used for femur fracture fixation, now includes post-operative stabilization indications. The company has expanded sizing options from XS to XXL and launched the product in Europe, Middle East, and Asia-Pacific markets. The DF2 Brace serves as an alternative to traditional spica casting for pediatric patients aged 6 months to 5 years, providing immobilization of the femur, knee, and hip. This expansion demonstrates OrthoPediatrics' commitment to improving pediatric orthopedic care globally.

OrthoPediatrics (Nasdaq: KIDS), a company dedicated to pediatric orthopedics, has announced its participation in two upcoming investor conferences in New York. Dave Bailey, President & Chief Executive Officer, will participate in fireside chats at the Stifel 2024 Healthcare Conference on November 19, 2024, at 10:55 am ET, and the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024, at 9:00 am ET. Audio webcasts of both discussions will be available on the company's investor relations website, with replays accessible after the events.